109 related articles for article (PubMed ID: 38862939)
1. Risk of breakthrough infection and hospitalisation after COVID-19 primary vaccination by HIV status in four Italian regions during 2021.
Mateo-Urdiales A; Fabiani M; Mayer F; Sacco C; Belleudi V; Da Cas R; Fotakis EA; De Angelis L; Cutillo M; Petrone D; Morciano C; Cannone A; Del Manso M; Riccardo F; Bella A; Menniti-Ippolito F; Pezzotti P; Spila Alegiani S; Massari M
BMC Public Health; 2024 Jun; 24(1):1569. PubMed ID: 38862939
[TBL] [Abstract][Full Text] [Related]
2. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
3. T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy.
Datwani S; Kalikawe R; Waterworth R; Mwimanzi FM; Liang R; Sang Y; Lapointe HR; Cheung PK; Omondi FH; Duncan MC; Barad E; Speckmaier S; Moran-Garcia N; DeMarco ML; Hedgcock M; Costiniuk CT; Hull M; Harris M; Romney MG; Montaner JSG; Brumme ZL; Brockman MA
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793543
[TBL] [Abstract][Full Text] [Related]
4. Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.
Huang X; Yan Y; Su B; Xiao D; Yu M; Jin X; Duan J; Zhang X; Zheng S; Fang Y; Zhang T; Tang W; Wang L; Wang Z; Xu J
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215870
[TBL] [Abstract][Full Text] [Related]
5. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US.
Sun J; Zheng Q; Madhira V; Olex AL; Anzalone AJ; Vinson A; Singh JA; French E; Abraham AG; Mathew J; Safdar N; Agarwal G; Fitzgerald KC; Singh N; Topaloglu U; Chute CG; Mannon RB; Kirk GD; Patel RC;
JAMA Intern Med; 2022 Feb; 182(2):153-162. PubMed ID: 34962505
[TBL] [Abstract][Full Text] [Related]
6. Effect of SARS-CoV-2 Breakthrough Infection on HIV Reservoirs and T-Cell Immune Recovery in 3-Dose Vaccinated People Living with HIV.
Qu MM; Song B; Yang BP; Wang Z; Yu M; Zhang Y; Zhang C; Song JW; Fan X; Xu R; Zhang JY; Zhou CB; Du F; Wang FS; Huang HH; Jiao YM
Viruses; 2023 Dec; 15(12):. PubMed ID: 38140668
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States.
Coburn SB; Humes E; Lang R; Stewart C; Hogan BC; Gebo KA; Napravnik S; Edwards JK; Browne LE; Park LS; Justice AC; Gordon KS; Horberg MA; Certa JM; Watson E; Jefferson CR; Silverberg MJ; Skarbinski J; Leyden WA; Williams CF; Althoff KN;
JAMA Netw Open; 2022 Jun; 5(6):e2215934. PubMed ID: 35671054
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study.
Agrawal U; Katikireddi SV; McCowan C; Mulholland RH; Azcoaga-Lorenzo A; Amele S; Fagbamigbe AF; Vasileiou E; Grange Z; Shi T; Kerr S; Moore E; Murray JLK; Shah SA; Ritchie L; O'Reilly D; Stock SJ; Beggs J; Chuter A; Torabi F; Akbari A; Bedston S; McMenamin J; Wood R; Tang RSM; de Lusignan S; Hobbs FDR; Woolhouse M; Simpson CR; Robertson C; Sheikh A
Lancet Respir Med; 2021 Dec; 9(12):1439-1449. PubMed ID: 34599903
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes of Coronavirus Disease 2019 in People Living With Human Immunodeficiency Virus in South Korea: A Nationwide Population-Based Cohort Study.
Kim JY; Jeong Y; An H; Suh JW; Sohn JW; Yoon YK
Influenza Other Respir Viruses; 2024 Jun; 18(6):e13337. PubMed ID: 38857604
[TBL] [Abstract][Full Text] [Related]
11. Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnel.
Maltezou HC; Gamaletsou MN; Giannouchos TV; Koukou DM; Karapanou A; Sourri F; Syrimi N; Lemonakis N; Peskelidou E; Papanastasiou K; Souliotis K; Lourida A; Panagopoulos P; Hatzigeorgiou D; Sipsas NV
J Hosp Infect; 2023 Feb; 132():46-51. PubMed ID: 36473554
[TBL] [Abstract][Full Text] [Related]
12. Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar.
Abu-Raddad LJ; Chemaitelly H; Ayoub HH; Yassine HM; Benslimane FM; Al Khatib HA; Tang P; Hasan MR; Coyle P; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Butt AA; Al Romaihi HE; Al-Thani MH; Al Khal A; Bertollini R
JAMA; 2021 Nov; 326(19):1930-1939. PubMed ID: 34724027
[TBL] [Abstract][Full Text] [Related]
13. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ
Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
Sacco C; Del Manso M; Mateo-Urdiales A; Rota MC; Petrone D; Riccardo F; Bella A; Siddu A; Battilomo S; Proietti V; Popoli P; Menniti Ippolito F; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M;
Lancet; 2022 Jul; 400(10346):97-103. PubMed ID: 35780801
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 breakthrough infections among people living with and without HIV: A statewide cohort analysis.
Yang X; Zhang J; Liu Z; Chen S; Olatosi B; Poland GA; Weissman S; Li X
Int J Infect Dis; 2024 Feb; 139():21-27. PubMed ID: 38013151
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy.
Lombardi A; Villa S; Colaneri M; Scaglione G; Bai F; Varisco B; Bono V; Vena A; Dentone C; Russo C; Tettamanti M; Renisi G; Viero G; Azzarà C; Mantero M; Peyvandi F; Bassetti M; Marchetti G; Muscatello A; Nobili A; Gori A; Bandera A;
J Infect Public Health; 2024 Mar; 17(3):467-473. PubMed ID: 38262085
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry.
Liew J; Gianfrancesco M; Harrison C; Izadi Z; Rush S; Lawson-Tovey S; Jacobsohn L; Ja C; Hyrich KL; Gossec L; Strangfeld A; Carmona L; Schäfer M; Frãzao-Mateus E; Bulina I; Stafford F; Tufan A; Graver C; Yardımcı GK; Zepa J; Al Emadi S; Cook C; Abutiban F; Dey D; Katigbak G; Kaufman L; Kowalski E; Martínez-Martínez MU; Patel NJ; Reyes-Cordero G; Salido E; Smith E; Snow D; Sparks J; Wise L; Bhana S; Gore-Massy M; Grainger R; Hausmann J; Sirotich E; Sufka P; Wallace Z; Machado PM; Robinson PC; Yazdany J
RMD Open; 2022 Apr; 8(1):. PubMed ID: 35387864
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.
Danza P; Koo TH; Haddix M; Fisher R; Traub E; OYong K; Balter S
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(5):177-181. PubMed ID: 35113851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
